1. Market Research
  2. > All Companies
  3. > Pluristem Therapeutics Inc. - Product Pipeline Review - 2014

Pluristem Therapeutics Inc. - Product Pipeline Review - 2014

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 46 pages

Pluristem Therapeutics Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Pluristem Therapeutics Inc. - Product Pipeline Review - 2014’, provides an overview of the Pluristem Therapeutics Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pluristem Therapeutics Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pluristem Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pluristem Therapeutics Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pluristem Therapeutics Inc.’s pipeline products

Reasons to buy

- Evaluate Pluristem Therapeutics Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pluristem Therapeutics Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pluristem Therapeutics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pluristem Therapeutics Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pluristem Therapeutics Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pluristem Therapeutics Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Pluristem Therapeutics Inc. - Product Pipeline Review - 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pluristem Therapeutics Inc. Snapshot 5
Pluristem Therapeutics Inc. Overview 5
Key Information 5
Key Facts 5
Pluristem Therapeutics Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Pluristem Therapeutics Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pluristem Therapeutics Inc. - Pipeline Products Glance 13
Pluristem Therapeutics Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Pluristem Therapeutics Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Pluristem Therapeutics Inc. - Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
Pluristem Therapeutics Inc. - Drug Profiles 17
PLX Cells for Peripheral Artery Disease 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
PLX-ORTHO 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
PLX-BMP 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
PLX Cells for Acute Myocardial Infarction 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
PLX Cells for Aplastic Bone Marrow 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
PLX Cells For GvHD 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
PLX Cells for Inflammatory Bowel Disease 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
PLX Cells for Ischemic Stroke 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
PLX Cells for Multiple Sclerosis 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
PLX Cells For Neuropathic And Inflammatory Pain 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
PLX Cells For Pre-Eclampsia 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
PLX-PAD for Pulmonary Fibrosis 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Pluristem Therapeutics Inc. - Pipeline Analysis 32
Pluristem Therapeutics Inc. - Pipeline Products by Route of Administration 32
Pluristem Therapeutics Inc. - Pipeline Products by Molecule Type 33
Pluristem Therapeutics Inc. - Recent Pipeline Updates 34
Pluristem Therapeutics Inc. - Dormant Projects 43
Pluristem Therapeutics Inc. - Locations And Subsidiaries 44
Head Office 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables

Pluristem Therapeutics Inc., Key Information 5
Pluristem Therapeutics Inc., Key Facts 5
Pluristem Therapeutics Inc. - Pipeline by Indication, 2014 8
Pluristem Therapeutics Inc. - Pipeline by Stage of Development, 2014 9
Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, 2014 10
Pluristem Therapeutics Inc. - Partnered Products in Pipeline, 2014 11
Pluristem Therapeutics Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Pluristem Therapeutics Inc. - Phase II, 2014 13
Pluristem Therapeutics Inc. - Phase I, 2014 14
Pluristem Therapeutics Inc. - Preclinical, 2014 15
Pluristem Therapeutics Inc. - Unknown, 2014 16
Pluristem Therapeutics Inc. - Pipeline by Route of Administration, 2014 32
Pluristem Therapeutics Inc. - Pipeline by Molecule Type, 2014 33
Pluristem Therapeutics Inc. - Recent Pipeline Updates, 2014 34
Pluristem Therapeutics Inc. - Dormant Developmental Projects,2014 43

List of Figures

Pluristem Therapeutics Inc. - Pipeline by Top 10 Indication, 2014 7
Pluristem Therapeutics Inc. - Pipeline by Stage of Development, 2014 9
Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, 2014 10
Pluristem Therapeutics Inc. - Pipeline by Top 10 Route of Administration, 2014 32
Pluristem Therapeutics Inc. - Pipeline by Top 10 Molecule Type, 2014 33

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Isarna Therapeutics GmbH - Product Pipeline Review - 2015

Isarna Therapeutics GmbH - Product Pipeline Review - 2015

  • $ 1 500
  • Company report
  • March 2015
  • by Global Markets Direct

Isarna Therapeutics GmbH - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Isarna Therapeutics GmbH - Product Pipeline Review - 2015’, provides an overview of the Isarna Therapeutics ...

Nabriva Therapeutics AG - Product Pipeline Review - 2015

Nabriva Therapeutics AG - Product Pipeline Review - 2015

  • $ 1 500
  • Company report
  • March 2015
  • by Global Markets Direct

Nabriva Therapeutics AG - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Nabriva Therapeutics AG - Product Pipeline Review - 2015’, provides an overview of the Nabriva Therapeutics ...

Amarna Therapeutics B.V. - Product Pipeline Review - 2015

Amarna Therapeutics B.V. - Product Pipeline Review - 2015

  • $ 1 500
  • Company report
  • March 2015
  • by Global Markets Direct

Amarna Therapeutics B.V. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Amarna Therapeutics B.V. - Product Pipeline Review - 2015’, provides an overview of the Amarna Therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.